Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$11.37 USD

11.37
117,803

+0.04 (0.35%)

Updated Nov 5, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progresses Well

by Zacks Equity Research

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Bears are Losing Control Over Amicus Therapeutics (FOLD), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar?

by Zacks Equity Research

Amicus Therapeutics (FOLD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA

by Zacks Equity Research

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss

by Zacks Equity Research

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.

Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.

Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View

by Zacks Equity Research

Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.

Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.

Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View

by Zacks Equity Research

Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Will Amicus Therapeutics (FOLD) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.

Can Amicus Therapeutics (FOLD) Climb 77% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.